31 results about "Carboplatin" patented technology

The invention belongs to the field of anti-tumor compounds, and particularly relates to a preparation method of carboplatin-unsaturated fatty acid liposome, which comprises the following steps: S1, preparing lecithin into a lecithin solution; preparing unsaturated fatty acid into a fatty acid solution; preparing carboplatin into a carboplatin solution; s2, adding a lecithin solution and a fatty acid solution into an eggplant-shaped bottle, then adding chloroform or dichloromethane, uniformly mixing, and carrying out rotary evaporation to obtain a phospholipid membrane; s3, taking and preheating a carboplatin solution, adding the carboplatin solution into the phospholipid membrane after preheating, and performing ultrasonic hydration to obtain a liposome solution; s4, performing ultrasonic crushing on the liposome solution; and S5, filtering the ultrasonically crushed liposome solution to obtain the liposome. The invention also discloses an application of the carboplatin-unsaturated fatty acid liposome prepared by the preparation method in preparation of antitumor drugs. The problem that in the prior art, the curative effect and safety of a carboplatin drug are difficult to consider at the same time can be solved, and metastatic tumor cells can be effectively inhibited at low drug concentration.

The invention provides a compound of carboplatin and 1, 1-cyclobutane dicarboxylic acid and a detection method of the compound. A nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of the carboplatin and 1, 1-cyclobutane dicarboxylic acid eutectic compound in a D-(+)-glucose heavy water solution with the mass fraction of 5%, a nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of carboplatin in a 1.2. 3. 4-cyclobutane tetracarboxylic acid heavy water solution with the mass fraction of 2%, and a 1, 1-cyclobutane dicarboxylic acid eutectic compound with the mass fraction of 1, 1-cyclobutane dicarboxylic acid are measured. A nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of carboplatin and 1, 1-cyclobutane dicarboxylic acid in a D-(+)-glucose heavy water solution with the mass fraction of 5% are analyzed, and the structure of the carboplatin and 1, 1-cyclobutane dicarboxylic acid eutectic compound in water is determined by analyzing the chemical shift change of characteristic carbon atoms in the nuclear magnetic resonance carbon spectrum.

The invention belongs to the technical field of biological medicine, and provides a nano-carrier drug delivery system loaded with carboplatin as well as a preparation method and application of the nano-carrier drug delivery system. The preparation method comprises the following steps: (1) dissolving AZ-COOH, EDCI and HOBT in DMSO, and activating to obtain a first mixed solution; dSPE-PEG2000-NH2 and TEA are dissolved in DMSO (dimethyl sulfoxide), and a second mixed solution is obtained after stirring; dropwise adding the first mixed solution into the second mixed solution, reacting, dialyzing, and drying to obtain a nano-carrier DSPE-PEG-CAI; (2) dissolving the nano carrier DSPE-PEG-CAI and carboplatin in an organic solvent to obtain an organic phase; adding ultrapure water, continuously performing ultrasonic treatment, and volatilizing the organic solvent to obtain a water phase; and carrying out aqueous phase dialysis, and filtering to obtain a nano carboplatin DSPE-PEG-CAI-CBP aqueous solution. The carboplatin-loaded nano-carrier drug delivery system provided by the invention can improve the targeting property and intracellular enrichment degree of drugs, and passes through a biological barrier established by a tumor microenvironment, so that the targeting selectivity to triple negative breast cancer cells is enhanced, and the side effects of carboplatin treatment are reduced.

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.

The application relates to application of miRNA as a target point in preparation of a drug for treating non-small cell lung cancer, and belongs to the biomedical technology field. The application provides application of miR-423-5p or miR-135a-5p as a target point in preparation of a drug for treating non-small cell lung cancer, specifically, application of an expression inhibitor of miR-423-5p or an overexpression reagent of miR-135a-5p in preparation of a drug for treating non-small cell lung cancer. The expression inhibitor of miR-423-5p or the overexpression reagent of miR-135a-5p in the application can cause the proliferation and migration ability of representative cells A549 and NCI-H1703 of non-small cell lung cancer to decrease and promote the apoptosis of the cells, and combined treatment of tumor chemotherapy drugs cisplatin or carboplatin can enhance the growth inhibition on the above two cell lines.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The invention relates to the technical field of biological medicine, and discloses an activated cis-platinum reversible coordination complex, coordination nano-micelles thereof and application of the activated cis-platinum reversible coordination complex and the coordination nano-micelles. The activated cis-platinum reversible coordination complex is a complex formed by a coordination material and a metal platinum drug or an activated molecule thereof or a derivative thereof, and the coordination ratio of a coordination group in the coordination material to the metal platinum drug or the activated molecule thereof or the derivative thereof is less than or equal to 2: 1; the coordination material is a coordination phospholipid-like material or a coordination polymer material; the metal platinum medicine or the activated molecule or the derivative thereof is cis-platinum, carboplatin, lobaplatin, epithiaplatin, nedaplatin, oxaliplatin or the activated molecule or the derivative thereof. According to the activated cisplatin reversible coordination complex and the coordination nano-micelle and application thereof, the coordination nano-micelle not only can realize cisplatin controlled release regulated by iron ions, but also can reduce ferroptosis of renal tubular cells and related renal cells by chelating the iron ions, so that the renal toxicity of the cisplatin is efficiently inhibited, and the application value is wide.

Methods for treating non-small cell lung cancer (NSCLC) include the administration of a combination of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed. The methods are based on tumor mutational burden (TMB) assessment, with specific treatment regimens tailored to the mutational profile of the tumor. When a low tumor mutational burden is detected in a tumor sample, the combination therapy of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed is administered, offering enhanced therapeutic efficacy.

The present invention relates to methods of treating head and neck squamous cell carcinoma (HNSCC), such as metastatic or advanced HNSCC, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met) in addition to a PD-(L)1 axis inhibitor (pembrolizumab) and a platinum-based chemotherapy agent (carboplatin). In particular, the EGFR / c-Met antibody is amivantamab.

A device and method are taught for stimulating sympathetic nerves toward mitigating negative impacts to hematopoiesis. An autonomic nerve actuator and stimulator system with a graphic user interface (GUI), controller circuit which converts treatment parameters into a series of Building Block Waveforms (BBW) which are output to Current / Voltage Driver Circuitry (CDC) whose electrical stimulus (ES) outputs are coupled to one or more electrodes and / or electrode arrays positioned proximal specific nerve situations. The use of this in combination with conventional chemotherapy treatments, such as use of carboplatin, was found to significantly enhance hematopoiesis, with improvements in white and red blood cell counts, platelet concentration and hemoglobin concentration, in addition to other measurable characteristics which increased survival rates in the experimental groups tested.

The present invention relates to the technical field of biochemical detection, and discloses a nucleic acid detection composition for non-small cell lung cancer carboplatin resistance screening, the nucleic acid detection composition comprises a specific amplification primer pair of a targeting NFAT2 gene, a TaqMan detection probe, a hot start TaqDNA polymerase and a reaction buffer solution, the reaction buffer solution comprises ectoine and tetramethylammonium chloride, according to the method, carboplatin is blocked by a compact hydrated shell layer formed on the surface of enzyme through ectoine, and the hydrogen bond energy difference between basic groups of nucleic acid large grooves is eliminated by using tetramethylammonium chloride, so that the microcosmic functional phase splitting structure is constructed. Therefore, efficient protection of polymerase activity and regulation and control of primer hybridization specificity are synchronously realized in a single reaction system, and sensitivity and accuracy of drug-resistant gene detection in a complex clinical sample are improved.

The invention relates to an application of a combination of an anti-TROP-2 antibody coupling drug and an anti-PD-L1 antibody or other chemotherapeutic drugs such as carboplatin or cis-platinum and the like in preparation of drugs for preventing and / or treating tumor diseases, and the anti-TROP-2 antibody can be Sacituzumab.

Provided is a method to detect cancer biomarkers, wherein the biomarkers indicate whether a patient will be susceptible to a chemotherapeutic agent.

The invention discloses a poly (lactic acid-glycolic acid) copolymer composite fiber membrane as well as a preparation method and application thereof. The poly (lactic acid-glycolic acid) copolymer composite fiber membrane provided by the invention comprises a poly (lactic acid-glycolic acid) copolymer fiber matrix, a loaded chemotherapeutic drug and a copper-based metal organic framework, the loaded chemotherapeutic drugs comprise carmustine, carboplatin and etoposide; the copper-based metal organic framework is CuBDC; according to the invention, by optimizing the electrospinning liquid formula and the electrospinning process, the synergistic loading of the PLGA fiber membrane on the water-soluble drug, the hydrophobic drug and the copper-based MOF is successfully realized, and the problems of limited drug loading, short slow release period and single function of the current PLGA drug-loaded fiber membrane are solved.

The present disclosure relates to the treatment of solid cancers, such as breast cancer, colon cancer, and lung cancer (particularly non-small cell lung cancer (NSCLC)), in human subjects using anti-PD-1 antibodies as monotherapy or as combination therapy with, for example, chemotherapy and / or surgery. The treatments provided may be a combination of tiralizumab and chemotherapy prior to surgery, using different doses of tiralizumab in an auxiliary stage after surgery. Administration regimens may include administration of 200 mg of an anti-PD-1 antibody (e.g., tiralizumab) (e.g., every three weeks) followed by tumor resection, followed by administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and / or cis-platinum), and may further include pemetrexed (e.g., for non-squamous cancer) or paclitaxel (e.g., for squamous cancer).

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.

The invention belongs to the field of medicines, and discloses application of a carboplatin compound in preparation of medicines for preventing and treating pulmonary nodules. The research on the tumor treatment effect of the carboplatin compound shows that the carboplatin compound has a relatively good effect on pulmonary nodule treatment, and further experiments prove that the carboplatin compound ZC2377 can effectively treat pulmonary nodule, so that the carboplatin compound ZC2377 has relatively high application value.

The invention relates to a system for treating biliary tract cancer, which comprises a device for applying an alternating electric field to a target area of a patient, and is characterized in that the frequency of the alternating electric field is 100-300kHz, and the field intensity is 1-3V / cm; the patient suffers from biliary tract cancer and has, simultaneously or will be subjected to combined treatment of an immune checkpoint inhibitor and a chemical drug. The immune checkpoint inhibitor is an anti-PD-L1 antibody, and the anti-PD-L1 antibody is selected from a group consisting of a duvaleriumab, an averlumab, a suaglizumab and an atelizumab; the chemical drugs comprise chemical drugs based on platinum drugs and / or chemical drugs of anti-metabolic drugs, and the chemical drugs based on the platinum drugs comprise cis-platinum or carboplatin; and / or the chemical drug of the anti-metabolic drug contains gemcitabine. According to the system disclosed by the embodiment of the invention, proliferation of the biliary tract cancer cells can be inhibited, migration of the biliary tract cancer cells is inhibited, mitosis of the biliary tract cancer cells is interfered, and immunogenic death of the biliary tract cancer cells is promoted. The present disclosure also relates to a method of treating biliary tract cancer.

The invention discloses a mouse ovarian cancer carboplatin drug-resistant cell strain as well as a construction method and application thereof, and belongs to the field of biomedicine. According to the invention, a firefly luciferase gene is transfected and introduced into a mouse epithelial ovarian cancer ID8 cell strain through a lentiviral vector, and a cell strain (ID8-Luc) capable of stably expressing the luciferase gene is obtained through puromycin screening. In-vitro induction is carried out by gradually increasing the dosage of carboplatin, the carboplatin-resistant ID8-Luc cell strain is successfully constructed, the drug-resistant strength is high, and the drug-resistant stabilization time is long. The invention provides an efficient tool cell strain for exploring a tumor drug resistance mechanism and screening anti-tumor drugs and novel targeted drug-resistant drugs, and has a good application prospect.

Provided are a carboplatin complex and a pharmaceutical preparation thereof. The carboplatin complex is a complex formed by combining carboplatin and 1,1-cyclobutanedicarboxylic acid through two hydrogen bonds, each of the two hydrogen bonds is formed between a carbonyl oxygen of a carboplatin molecule and a carboxyl hydrogen of a 1,1-cyclobutanedicarboxylic acid molecule. The present disclosure further provides use of the carboplatin complex in manufacture of an antitumor drug, an antibacterial drug, an antifungal drug, or an antiviral drug, and a quality control method for the carboplatin complex.

The invention belongs to the field of medicines, and discloses application of a carboplatin compound in preparation of medicines for preventing and treating psoriasis. According to the present invention, in the tumor treatment effect research of the carboplatin compound ZC2377, the psoriasis treatment activity of the carboplatin compound ZC2377 is accidentally found, such that the result is verified through the further experiment, and the practical application value of the carboplatin compound ZC2377 is provided.

A treatment of lung cancer, particularly small cell lung cancer, in a human subject using an anti-PD-1 antibody and optionally a chemotherapy is provided. In some embodiments, the small cell lung cancer is an advanced (e.g., locally advanced) or diffusive (e.g., stage III or stage IV), non-resectable or metastatic (e.g., with liver, lung or lymph node metastasis, e.g., with 2, 3 or more metastatic sites) lung cancer. In some embodiments, the chemotherapy is carboplatin and / or cis-platinum, and optionally further etoposide. In some embodiments, the SCLC is a small cell carcinoma. In some embodiments, the SCLC is a complex small cell carcinoma. In some embodiments, the treatment is a first-line treatment. In some embodiments, the claimed therapies are effective in the treatment of SCLC. In some embodiments, the human subject is a responder to a treatment by at least one measurement of a response to the treatment.

A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg / ml to 2 mg / ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.

The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding oxaliplatin and carboplatin derivatives, as well as their use in therapy, particularly for the treatment or prevention of cancer. (Formula (I))

Disclosed herein are methods of using amivantamab in combination with carboplatin and pemetrexed for the treatment of non-small cell lung cancer (NSCLC).

The invention provides a method for testing a crystal structure of a crystal form of a carboplatin and 1, 1-cyclobutane dicarboxylic acid eutectic compound and the crystal structure. According to the invention, crystal powder of the eutectic compound of carboplatin and 1, 1-cyclobutane dicarboxylic acid is prepared, and Micro-ED (microcrystal diffraction) is utilized to measure and obtain the crystal structure of the crystal form of carboplatin and 1, 1-cyclobutane dicarboxylic acid. Through the structure, the combination and positions of hydrogen bonds in two molecules can be determined, preparation of an aqueous solution is facilitated, and good water solubility and stability are explained.

The invention discloses a preparation method of cis-amino-hydrate-1, 1-cyclobutane dicarboxylic acid platinum (II) and a preparation method of the cis-amino-hydrate-1, 1-cyclobutane dicarboxylic acid platinum (II). The preparation method comprises the following steps: by taking potassium trichloroammine platinate and 1, 1-cyclobutane dicarboxylic acid as starting materials, sequentially neutralizing the 1, 1-cyclobutane dicarboxylic acid with alkali and carrying out precipitation reaction on the 1, 1-cyclobutane dicarboxylic acid and silver nitrate to prepare silver 1, 1-cyclobutane dicarboxylic acid, and then respectively reacting the silver 1, 1-cyclobutane dicarboxylic acid with the potassium trichloroammine platinate and the silver nitrate to prepare the cis-amino-water-1, 1-cyclobutane dicarboxylic acid platinum (II). The method for preparing the cis-amino-hydrate-1, 1-cyclobutane dicarboxylic acid platinum (II) has the advantages that the reaction steps are short, the materials are easy to purchase, the operability is high, and the obtained product has the characteristics of high yield and high purity, and meets the calibration and sample inspection requirements of self-made reference substances of related substances in carboplatin products.

A method of treating cancer cells to achieve apoptosis including contacting the cancer cells with a porous particulate nanocomposite in an amount sufficient to kill the cancer cells. The porous particulate nanocomposite contains a magnetic nickel ferrite (NiFe2O4) having an inverse spinel crystal structure; and, monodisperse spherical silica (Sil) particles onto which the magnetic NiFe2O4 is dispersed. The nanocomposite is functionalized with cis-diammine (cyclobutane-1,1-dicarboxylate-O,O′)platinum(II) (carboplatin or Carbpt) and folic acid (FA). The cancer cells are cells of colon cancer, colorectal cancer and / or cervical cancer.